Manuel H. Janeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manuel H. Janeiro has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jose Antonio Rodriguez
Atherosclerosis Research Laboratory, Division of Cardiovascular Sciences, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain
1 shared publication - Josune Orbe
Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain
1 shared publication - Leyre Sanchez de Muniain
Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain
1 shared publication - Maite Solas
Department of Pharmaceutical Sciences, University of Navarra, Pamplona, Spain
1 shared publication - Maria Javier Ramirez
Department of Pharmacology and Toxicology, University of Navarra, 31008 Pamplona, Spain
1 shared publication - Paula Escalada
Department of Pharmaceutical Sciences University of Navarra Pamplona Spain
1 shared publication
Latest Publications
- Open Access
- 16 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17557
Trimethylamine N-Oxide as a Mediator Linking Peripheral to Central Inflammation: An In Vitro Study
In this study, the plausible role of trimethylamine N-oxide (TMAO), a microbiota metabolite, was investigated as a link between peripheral inflammation and the inflammation of the central nervous system using different cell lines. TMAO treatment favored the differentiation of adipocytes from preadipocytes (3T3-L1 cell line). In macrophages (RAW 264.7 cell line), which infiltrate adipose tissue in obesity, TMAO increased the expression of pro-inflammatory cytokines. The treatment with 200 μM of TMAO seemed to disrupt the blood–brain barrier as it induced a significant decrease in the expression of occludin in hCMECs. TMAO also increased the expression of pro-inflammatory cytokines in primary neuronal cultures, induced a pro-inflammatory state in primary microglial cultures, and promoted phagocytosis. Data obtained from this project suggest that microbial dysbiosis and increased TMAO secretion could be a key link between peripheral and central inflammation. Thus, TMAO-decreasing compounds may be a promising therapeutic strategy for neurodegenerative diseases.
- 16 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17557
Open AccessTrimethylamine N-Oxide as a Mediator Linking Peripheral to Central Inflammation: An In Vitro Study
In this study, the plausible role of trimethylamine N-oxide (TMAO), a microbiota metabolite, was investigated as a link between peripheral inflammation and the inflammation of the central nervous system using different cell lines. TMAO treatment favored the differentiation of adipocytes from preadipocytes (3T3-L1 cell line). In macrophages (RAW 264.7 cell line), which infiltrate adipose tissue in obesity, TMAO increased the expression of pro-inflammatory cytokines. The treatment with 200 μM of TMAO seemed to disrupt the blood–brain barrier as it induced a significant decrease in the expression of occludin in hCMECs. TMAO also increased the expression of pro-inflammatory cytokines in primary neuronal cultures, induced a pro-inflammatory state in primary microglial cultures, and promoted phagocytosis. Data obtained from this project suggest that microbial dysbiosis and increased TMAO secretion could be a key link between peripheral and central inflammation. Thus, TMAO-decreasing compounds may be a promising therapeutic strategy for neurodegenerative diseases.